AngioDynamics (NASDAQ:ANGO) Issues FY 2022 Earnings Guidance

AngioDynamics (NASDAQ:ANGO) updated its FY 2022 earnings guidance on Thursday. The company provided EPS guidance of $0.000-$0.050 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.010. The company issued revenue guidance of $310 million-$315 million, compared to the consensus revenue estimate of $307.82 million.

Shares of NASDAQ ANGO opened at $25.93 on Thursday. AngioDynamics has a one year low of $10.17 and a one year high of $30.25. The firm has a market capitalization of $1.00 billion, a PE ratio of -31.62 and a beta of 0.83. The company has a current ratio of 2.45, a quick ratio of 1.60 and a debt-to-equity ratio of 0.05. The business has a 50-day moving average price of $26.71 and a two-hundred day moving average price of $25.56.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings data on Thursday, September 30th. The medical instruments supplier reported ($0.02) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.05) by $0.03. AngioDynamics had a positive return on equity of 0.41% and a negative net margin of 10.84%. The firm had revenue of $77.00 million during the quarter, compared to analyst estimates of $71.31 million. During the same period last year, the company posted $0.02 EPS. The business’s quarterly revenue was up 9.7% compared to the same quarter last year. Research analysts anticipate that AngioDynamics will post 0.01 EPS for the current year.

ANGO has been the subject of a number of research reports. TheStreet upgraded AngioDynamics from a d+ rating to a c rating in a research report on Tuesday, July 13th. Oppenheimer started coverage on AngioDynamics in a report on Friday, August 20th. They set a market perform rating for the company. Canaccord Genuity lifted their price target on AngioDynamics from $24.00 to $28.00 and gave the company a hold rating in a report on Wednesday, July 14th. Finally, Raymond James lifted their price target on AngioDynamics from $27.00 to $32.00 and gave the company a strong-buy rating in a report on Friday, July 9th. Three equities research analysts have rated the stock with a hold rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, AngioDynamics has an average rating of Buy and an average price target of $27.33.

In related news, SVP Chad Thomas Campbell sold 10,748 shares of the firm’s stock in a transaction that occurred on Tuesday, October 5th. The stock was sold at an average price of $27.15, for a total value of $291,808.20. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 3.80% of the stock is currently owned by company insiders.

A hedge fund recently raised its stake in AngioDynamics stock. Morgan Stanley lifted its position in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 88.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 289,456 shares of the medical instruments supplier’s stock after purchasing an additional 135,460 shares during the quarter. Morgan Stanley owned approximately 0.75% of AngioDynamics worth $7,853,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 96.45% of the company’s stock.

About AngioDynamics

AngioDynamics, Inc is a medical device company, which engages in the development, manufacture, and sale of medical devices for vascular access, surgery, peripheral vascular disease, and oncology. It offers ablation systems, fluid management systems, vascular access, angiographic, drainage. thrombolytic, and venous products.

Featured Story: Why is momentum important to successful trading?

Earnings History and Estimates for AngioDynamics (NASDAQ:ANGO)

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with's FREE daily email newsletter.